Nuclear Hormone Receptor (NHR) In Vitro Assays and Profiling Solutions

Eurofins Discovery offers a broad portfolio of nuclear hormone receptors (NHR) assays that can help provide a complete profile of your drug or compound, and give you a better sense of its gene-regulating properties.
 
NHR receptors have been important therapeutic targets in the pathology of cancer, inflammation, and many other diseases for over 20 years. NHRs are a large superfamily of ligand-activated transcription factors that consist of two subtypes: steroid and non-steroid. These receptors serve as “on-off” switches for genes that regulate cell differentiation, proliferation, and metabolism, and thus can play a role in the pathology of cancer, cardiovascular disease, inflammation, and reproduction. As with many receptors, ligand binding induces a conformational change in the receptor, but unique to nuclear receptors is their ability to up- or down-regulate gene expression. This ability makes nuclear receptors interesting therapeutic and liability targets.
 
Our scientists developed a portfolio of binding, cell-based, protein-protein interaction NHR, nuclear translocation and co-activator recruitment assays. These assays can help provide a complete profile of your drug or compound, and gain a more focused sense of its gene-regulating properties, providing key data to help advance your project.